Novartis, Amgen team on migraine, Alzheimer’s drug development
BASEL, Switzerland — Novartis and Amgen are joining forces to develop and commercialize neuroscience treatments in both their pipelines the companies announced Tuesday. The collaboration will see them working on a BACE inhibitor program to treat Alzheimer’s disease and developing Amgen’s migraine drugs.
"This Novartis collaboration with Amgen highlights our clear commitment to neuroscience and to bring multiple, new targeted therapies to patients living with Alzheimer's disease and migraine, where the unmet medical need remains high." Novartis Pharmaceuticals head David Epstein said.
The Amgen partnership comes on the heels of Novartis’ recent acquisition of Spinifex Phamceuticals, which added a compound for neuropathic pain to the company’s portfolio, and its agreement to acquire multiple sclerosis treatment Ofatumumab from GlaxoSmithKline.
QS1 offers myDataMart through FDS partnership
Sandoz introduces rivastigmine patch
PRINCETON, N.J. — Sandoz on Wednesday introduced rivastigmine transdermal system, a generic version of Exelon Patch1, in the United States.
The rivastigmine patch is used to treat mild, moderate and severe memory problems associated with both Alzheimer’s disease and Parkinson’s disease.
"Sandoz is pleased to make rivastigmine patch available as a generic option for patients with memory problems associated with Alzheimer’s disease,” Sandoz president Peter Goldschmidt said. “Rivastigmine has been studied for more than a decade in clinical trials and is the only Alzheimer's disease treatment that comes in the form of a patch with the medication absorbed through the skin.”
For the 12 months ending in June, U.S. sales for the rivastigmine patch were $646 million, according to the company. Sandoz will sell rivastigmine in 13.3 mg strength, the same strength as the brand.